COVID in Post Vaccinated individuals- Beacon of Light

Authors – VK Sashindran¹ , K Rajesh¹ , Ankur Nigam² , Sourya Sourabh Mohakuda^{*1}, Navin Bhati¹ , Mohapatra D¹

1- Dept of Internal Medicine, 7 Air Force Hospital, Kanpur

2- Public Health Specialist, Gangtok

***corresponding author**

Introduction- COVISHIELD and COVAXIN have been introduced post rapid approval as COVID vaccines in India, which has the second most COVID cases across countries. These vaccines are being administered in a two-dose schedule from 16 Jan 2021. This study deals with the clinical profile of individuals who developed COVID infection post-COVID vaccination. This is the first study of similar nature in India.

Methodology – The study population comprised of individuals who were detected to be COVID positive 04 weeks post-vaccination and were compared with individuals detected positive within the first 04 weeks of vaccination. Data was collected in a digital questionnaire format and analyzed with SPSS v-23 software. Clinical features were profiled in detail. Chi-square analysis was done to find out the association of various demographic features with the severity of the disease.

Results – In the study population, fever was the commonest symptom (75.1%) followed by anosmia (72.1%), and shortness of breath (16.3%). There was a lower incidence of fever, cough, dyspnea, and requirement of hospitalization in the study population as compared to the control group and previous epidemiological data. The time required for complete recovery and disease severity was favorable in our study population. There was a significant correlation in the rate of hospitalization among the study group and the comparative group ($p=0.0001$) and between the number of dosage of COVID vaccine with the lowest SpO₂ recorded ($p=0.001$).

Conclusion - This study will boost the ongoing initiative of having a maximal vaccinated population countrywide and emphasize the need for two doses of vaccination.

KEYWORDS – COVISHIELD, COVAXIN, EFFICACY, VACCINATION

Introduction:

Severe Acute Respiratory Syndrome Corona Virus 2 (SARS CoV2), a coronavirus, causing COVID 19 infection was declared a pandemic on 11 Mar 2020 by the World Health Organization [1]. The pandemic has not only inflicted mortality and morbidity across the human race but has also crippled the economies of affected nations. The imperative to control this disease has encouraged vaccine research worldwide. The severe second and third waves of infections have made the world realize that rapid vaccination of as many people as possible with an effective vaccine is the only lasting solution.

Vaccination against the disease was launched in India on 16 Jan 2021 with healthcare workers, frontline workers, and elderly above 60 years being the first beneficiaries. Two vaccines have so far been used in India: COVISHIELD and COVAXIN. The COVISHIELD vaccine is a viral-vectored vaccine, developed by the Serum Institute of India in line with the vaccine developed in the UK by Jenner Institute, University of Oxford. COVAXIN is an inactivated virus vaccine, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research [2].

During the early stages of vaccination, there were public concerns about the safety and efficacy of the vaccines. This was mainly due to the rapid approvals given to their usage [3, 4]. Subsequently, several scientific publications have validated the safety of these vaccines [5]. The efficacy as determined by seroconversion after the first and second doses of COVISHIELD is 91% and 100% respectively and that of COVAXIN is 98.3% at 56 days post-vaccination [6,7].

Various studies have also shown that vaccination confers immunity and prevents progression to severe disease. In this study, we have highlighted the clinical profile of patients who were detected to be COVID positive post-vaccination. To the best of our knowledge, this is the first paper on the analysis of the clinical profile of COVID illness in post-vaccination individuals in India.

Materials and methods:

This descriptive observational study was conducted in individuals under the area of responsibility of a tertiary care center in Northern India with a premise to study the clinical profile of patients with COVID infection and various factors associated with severity of disease post-COVID vaccination. All COVID positive patients who developed COVID at least 4 weeks after the first dose of COVID vaccination were eligible for enrollment. Informed consent was taken from all participants. The subjects were administered a questionnaire via digital means during the period from Apr 2021 to May 2021. Data of all the beneficiaries were compiled and collated in an excel sheet and was analyzed after data cleaning using SPSS v-23.

This is the first study highlighting clinical features in COVID positive individuals post-vaccination to the best of our knowledge. Individuals who were tested positive by rapid antigen test/RT-PCR were taken as COVID positive patients. The lowest oxygen saturation on pulse oximeter (Spo2) recorded by the study participants was used as a surrogate marker to assess the severity of the disease. The mild disease was said to be present if the lowest Spo2 recorded by

study participant was more than or equal to 94%, SpO₂ of 90%-93%, and below 90% were considered moderate and severe COVID respectively. For this study, post-vaccination COVID infection was defined as a confirmed COVID positive case who has taken at least one dose of COVISHIELD and COVAXIN four weeks before having COVID infection. This time cut-off was taken as the time taken for seroconversion after COVID vaccination is approximately 04 weeks [6,7]. Those who developed COVID less than four weeks after the first dose of vaccination were enrolled in the comparative arm of the study.

Statistical analysis:

Descriptive statistics (frequency and percentages) were calculated for sample demographic characteristics and clinical features of the participants. Chi-square analysis was done to find out the association of various demographic features with the severity of disease among the study participants. The data of individuals with COVID infection following COVID vaccination after single and two doses was analyzed separately and interpreted. Binary logistic regression was done for variables that were found to have a statistically significant association with the outcome of interest.

Results:

There were 168 participants in the study group and 42 participants in the comparative group whose mean age was 37.18(+/- 9.38) & 40.36(+/- 11.274) respectively. The study population comprised 140 (83.3%) males and 28 (16.7%) females in the study group & 31 (73.8%) males and 11(26.2%) females in the comparative group respectively. The study population was divided into 05 subgroups based on their age profile. 33(19.6%) of the participants had at least one comorbid condition against 16 (38.1%) in the comparative group. Demographic features of the entire study population are given in Table-01.

Table-01: Demographic features of the study population & comparative group

	Study population Total (N=168) n(%)	Comparative group (N=42) n(%)
Gender		
Male	140 (83.3)	31 (73.8)
Female	28 (16.7)	11 (26.2)
Age (years)		
20-30	40 (23.8)	12 (28.6)
30-40	73 (43.5)	12 (28.6)
40-50	34 (20.2)	09 (21.4)
50-60	19 (11.3)	08 (19.0)
60-70	02 (1.2)	01 (2.4)
Comorbidity		
Present	33 (19.6)	16 (38.1)
Absent	135 (80.4)	26 (61.9)
Profession		
Health care worker	54 (32.1)	02 (4.8)
Front line worker	64 (38.1)	12 (28.6)
Others	50 (29.8)	28 (66.7)

162(96.4%) of the study participants received COVISHIELD against 40(95.2%) of the comparative group, One hundred and fifty-eight (94.0%) participants of the study population received both doses of the vaccine. Vaccination details of the study population are given in table-02.

Table-02: Vaccination details of the study population

	Total (N=168) n(%)	
Type of Vaccine administered		
Covishield	162 (96.4)	
Covaxin	06 (3.6)	
Number of doses administered		
First dose	10 (6.0)	
Second dose	158 (94.0)	
Duration after vaccination when the individual became COVID positive		
	After 1st Dose	After 2nd Dose
Less than 2 weeks	-	25 (15.8)
2-4 weeks	-	34 (21.5)
4-8 weeks	10 (100)	74 (46.8)
>8 weeks	-	25 (15.8)

One hundred and twenty-nine (76.8%) of the study participants were symptomatic for COVID infection and 29(17.3%) of them required hospitalization. Twenty-nine (69.0%) of the comparative group were symptomatic for COVID infection and 20 (47.6%) of them required hospitalization. Fever was the predominant symptom 122 (77.2%), followed by loss of smell/taste and cough among the study group participants. A similar trend was observed among the comparative group. A significant association was found for shortness of breath and the lowest SpO2 recorded among the participants when compared in both arms. Clinical features of the study population and comparative group with symptomatic COVID infection are given in Table-03.

Table-03: Clinical features of the study population & comparative group among symptomatic individuals

Clinical Characteristics		Study population Total n (%)	Comparative group n (%)	p-value
1. Fever				
(a) Present		97 (75.1)	25 (86.2)	.201
Absent		32 (24.9)	04 (13.8)	
(b) Duration of fever	<5 days	69 (71.1)	17 (68.0)	
	5-10 days	25 (25.8)	08 (32.0)	
	>10 Days	03 (3.1)	-	
(c) Maximum recorded temp	<100	27 (27.8)	08 (32.0)	
	100-102	64 (66.0)	13 (52.0)	
	102-104	05 (5.2)	03 (12.0)	
	>104	01 (1.0)	01 (4.0)	
2. Cough				
(a) Present		90 (69.8)	19 (65.5)	.654
Absent		39 (30.2)	10 (34.5)	
(b) Type of cough	Dry	65 (72.2)	11 (57.9)	
	Productive	25 (27.8)	08 (42.1)	
(d) Duration of cough	<5 days	32 (35.6)	07 (36.8)	
	5-10 days	28 (31.1)	10 (52.7)	
	>10 Days	30 (33.3)	02 (10.5)	

3. Shortness of breath				
(a) Present		21 (16.3)	08 (27.6)	.004
Absent		108 (83.7)	21 (72.4)	
(b) Onset of shortness of breath	<2days	08 (38.1)	02 (25.0)	
	2-6 days	10 (47.6)	04 (50.0)	
	>6 days	3. (14.3)	2. (25.0)	
4 Lowest Spo2 recorded	80-90	02 (1.6)	03 (10.3)	.001
	90-94	13 (10.0)	08 (27.6)	
	>94	114 (88.4)	18 (62.1)	
5 Loss of smell/taste				
(a) Present		93. (72.1)	22. (75.9)	0.169
Absent		36 (27.9)	07 (24.1)	
6. Gastrointestinal symptoms				
(a) Present		42 (32.6)	09 (31.0)	0.874
Absent		87 (67.4)	20 (69.0)	

The Chi-square test was used to find out the association of various demographic features with the outcome of interest among the study participants. It was found that the number of dosage of the COVID vaccine had a significant association with the lowest Spo2 recorded among the study participants (Table-04).

Table-04: Association of various demographic characteristics among the study participants with the severity of disease

Demographic characteristics	Lowest Spo2 recorded		p-Value
	Mild	Moderate/Severe	
Gender			
Male	96	11	.286
Female	18	04	
Lag period between vaccine administration and being detected COVID positive			
<2wks	17	01	.735
2-4 wks	23	04	
4-8 wks	54	06	
>8 wks	14	01	
Number of dose of COVID vaccine			
Single Dose	06	03	.03
Two Doses	108	12	
Duration for full recovery			
	Infection after the first dose	Infection after two doses	
<1 wk	01	20	.234
1-2 wk	04	34	
2-4 wk	01	45	
>4 wk	03	20	
Number of dose of COVID vaccine	Symptomatic for COVID infection		
	Yes	No	
1st Dose	9	1	.307
2nd Dose	120	38	

	Hospitalization of individuals		
	Yes	No	
Study group	29	139	.0001
Comparative group	20	22	

Binary logistic regression was further applied to the variables which had a significant association with the outcome of interest. The odds of milder infection after both the doses of COVID vaccine among the study group was 1.5 times that after a single dose ($p=.05$) (Table-05).

Table-05: Binary Logistic regression for COVID Vaccine minor reactions by demographic characteristics

	OR	SE	95% CI	p-Value
Mild Infection after the first dose	REF	REF	REF	
Mild Infection after two doses	1.5	.770	0.995-20.34	.05

Discussion:

Initial epidemiological data shows that COVID-19 disease presents as mild cases in 81%, severe cases in 14%, and as critical cases in 5%. It is also associated with a mortality rate of about 2.5% [8]. In addition, clustering of cases in a limited geographical area over a short time overwhelms health care facilities. Mass vaccination is considered the only viable strategy to mitigate viral pandemics. This descriptive study demonstrates the clinical profile of individuals developing COVID infection post-vaccination.

Our study population was relatively young with a mean age of 37.18 (± 9.38) and this was comparable with the comparative population. The proportion of individuals with co-morbid conditions is comparable to the general population [9]. With this second wave of COVID affecting the younger population, our study population can be considered as a suitable representation of the general population [10]. Most of our study population (96.4%) received COVISHIELD with 94% of the study population having taken both doses of vaccination. As the

subjects did not have a choice as to which vaccine they could take, interpretation on the choice of the vaccine was not done.

Fever was the most predominant symptom, followed by loss of smell/taste in 75.1% and 72.1% of the study population respectively. In a meta-analysis done by Li et al., fever was seen in 88.5%, cough in 68.6%, dyspnea in 21.9%, and gastrointestinal symptoms in 8.7% of symptomatic individuals [8]. There was a lower incidence of fever, cough, and shortness of breath in our study population as compared to both the comparative group and the study by Li et al. However, the above-referenced study was only a meta-analysis of the clinical profile of COVID patients and did not focus on post-vaccination COVID.

The clinical profile of post-vaccination COVID was that of a short febrile illness with 70.5% of the febrile patients having fever for less than 5 days. In a study on the clinical profile of COVID infection in the non-vaccinated population, Raman Sharma et al found the median duration of fever to be 12 days [11]. The duration of fever is considerably lower among our vaccinated subjects. As per our SpO2 based severity classification, 83.5% had mild, 13.3% moderate, and 3.2% severe disease. Saturation below 80% was not recorded in any of our subjects. In the study by Li et al, on non-vaccinated COVID patients, 14% had severe and 5% had critical disease[8]. Vaccination thus seems to mitigate critical and severe disease.

The duration for complete recovery in our study as shown in the results is considerably faster than that of data published by MP Barman et al where less than 4% of the patients had recovered in 10 days and it took 25 days for 50% of the patients to recover fully [12].

There was a significant association ($p=0.0001$) with a decreased rate of hospitalization among the study population as compared to the comparative group. This is much lower than the average rate of hospitalization required in COVID among unvaccinated individuals.[13]

There was a significant correlation between the number of dosages of the COVID vaccine with the lowest SpO2 recorded ($p=0.001$) with the odds of having mild infection after both doses of the vaccine among the study group was 1.5 times than that after a single dose. ($p=0.05$). Despite an extensive search, we could not find any published study analyzing similar data. This translates into a better outcome of COVID with two doses of vaccine.

Conclusion:

This study on post-vaccination COVID infection in India shows the numerous benefits of vaccination and should be a guiding light for the administration to continue striving to vaccinate most of the population quickly.

Funding – Nil

Conflict of interest - Nil

References:

1. AgrawalS, Goel AD, Gupta N. Emerging prophylaxis strategies against COVID-19. *Monaldi Arch Chest Dis*. 2020 Mar 30;90(1). doi: 10.4081/monaldi.2020.1289. PMID: 32231348.
2. SharmaO, Sultan AA, Ding H, TrigglerCR. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. *Front Immunol*. 2020 Oct 14;11:585354. doi: 10.3389/fimmu.2020.585354. PMID: 33163000; PMCID: PMC7591699.
3. PalamenghiL, BarellloS, BocciaS, Graffigna G. Mistrust in biomedical research and vaccine hesitancy: the forefront challenge in the battle against COVID-19 in Italy. *EurJEpidemiol*. 2020 Aug;35(8):785-788. doi: 10.1007/s10654-020-00675-8. Epub 2020 Aug 17. PMID: 32808095; PMCID: PMC7431109.
4. Lin Y, Hu Z, Zhao Q, Alias H, Danaee M, Wong LP. Understanding COVID-19 vaccine demand and hesitancy: A nationwide online survey in China. *PLoS Negl Trop Dis*. 2020 Dec 17;14(12):e0008961. doi: 10.1371/journal.pntd.0008961. PMID: 33332359; PMCID: PMC7775119.
5. Mohakuda, SouryaSourabh& Nigam, Ankur& Rajesh, K &Sashindran, V& Sharma, Himanshu& Singh, Bhupender& Kaur, Ramanjot&Thawal, Mamta. (2021). CovishieldCOVID Vaccine In India -Demystifying Myths -Early Multicentric Safety Study. 10.13140/Rg.2.2.14623.69285.
6. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, Dold C, Faust SN, Finn A, Flaxman AL, Hallis B, Heath P, Jenkin D, Lazarus R, Makinson R, Minassian AM, Pollock KM, Ramasamy M, Robinson H, Snape M, Tarrant R, Voysey M, Green C, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *Lancet*. 2020 Aug 15;396(10249):467-478. doi: 10.1016/S0140-6736(20)31604-4. Epub 2020 Jul 20. Erratum in: *Lancet*. 2020 Aug 15;396(10249):466. Erratum in: *Lancet*. 2020 Dec 12;396(10266):1884. PMID: 32702298; PMCID: PMC7445431.
7. Ella R, Reddy S, Jogdand H, Sarangi V, Ganneru B, Prasad S, Das D, Raju D, Praturi U, Sapkal G, Yadav P, Reddy P, Verma S, Singh C, Redkar SV, Gillurkar CS, Kushwaha JS, Mohapatra S, Bhate A, Rai S, Panda S, Abraham P, Gupta N, Ella K, Bhargava B, Vadrevu KM. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. *Lancet Infect Dis*. 2021 Mar 8:S1473-3099(21)00070-0. doi: 10.1016/S1473-3099(21)00070-0. Epub ahead of print. PMID: 33705727.
8. Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, Zhang HY, Sun W, Wang Y. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-

- analysis. *J Med Virol.* 2020 Jun;92(6):577-583. doi: 10.1002/jmv.25757. Epub 2020 Mar 23. PMID: 32162702; PMCID: PMC7228329.
9. Boutayeb, A., Boutayeb, S. The burden of non communicable diseases in developing countries. *Int J Equity Health* **4**, 2 (2005). <https://doi.org/10.1186/1475-9276-4-2>
10. Palmieri L, Palmer K, Lo Noce C, Meli P, Giuliano M, Floridia M, Tamburo de Bella M, Piccioli A, Brusaferrero S, Onder G; Italian National Institute of Health COVID-19 Mortality Group (*). Differences in the clinical characteristics of COVID-19 patients who died in hospital during different phases of the pandemic: national data from Italy. *Aging ClinExp Res.* 2021 Jan;33(1):193-199. doi: 10.1007/s40520-020-01764-0. Epub 2020 Dec 21. PMID: 33345291; PMCID: PMC7750107.
11. Sharma R., Agarwal M., Gupta M., Somendra S., Saxena S.K. (2020) Clinical Characteristics and Differential Clinical Diagnosis of Novel Coronavirus Disease 2019 (COVID-19). In: Saxena S. (eds) *Coronavirus Disease 2019 (COVID-19). Medical Virology: From Pathogenesis to Disease Control.* Springer, Singapore. https://doi.org/10.1007/978-981-15-4814-7_6
12. Barman MP, Rahman T, Bora K, Borgohain C. COVID-19 pandemic and its recovery time of patients in India: A pilot study. *Diabetes MetabSyndr.* 2020 Sep-Oct;14(5):1205-1211. doi: 10.1016/j.dsx.2020.07.004. Epub 2020 Jul 9. PMID: 32673841; PMCID: PMC7343664.
13. Garg, S., Kim, L., Whitaker, M., O'Halloran, A., Cummings, C., Holstein, R., Prill, M., Chai, S. J., Kirley, P. D., Alden, N. B., Kawasaki, B., Yousey-Hindes, K., Niccolai, L., Anderson, E. J., Openo, K. P., Weigel, A., Monroe, M. L., Ryan, P., Henderson, J., Kim, S., ... Fry, A. (2020). Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020. *MMWR. Morbidity and mortality weekly report*, 69(15), 458–464. <https://doi.org/10.15585/mmwr.mm6915e>